These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9051242

  • 21. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue.
    Spitzer TR, Cirenza E, McAfee S, Foelber R, Zarzin J, Cahill R, Mazumder A.
    Bone Marrow Transplant; 1995 Apr; 15(4):537-42. PubMed ID: 7655378
    [Abstract] [Full Text] [Related]

  • 22. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
    Stemmer SM, Pfeffer MR, Rizel S, Hardan I, Goffman J, Gezin A, Neumann A, Kitsios P, Alezra D, Brenner HJ.
    Cancer; 2001 Jun 01; 91(11):1983-91. PubMed ID: 11391576
    [Abstract] [Full Text] [Related]

  • 23. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM, Grinblatt DL, Malloy R, Williams SF.
    Cancer; 1998 Oct 15; 83(8):1540-5. PubMed ID: 9781947
    [Abstract] [Full Text] [Related]

  • 24. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R.
    Br J Cancer; 1999 Mar 15; 79(9-10):1500-7. PubMed ID: 10188897
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
    Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH.
    N Engl J Med; 2000 Apr 13; 342(15):1069-76. PubMed ID: 10760307
    [Abstract] [Full Text] [Related]

  • 27. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
    Martín M, Casado A, Llorente L, López Martín JA, Rodríguez Lescure A, Nieto Y, Ayala F, Pérez Calvo J, Alonso JL, Pérez López C, Villegas A, Díaz-Rubio E.
    Med Clin (Barc); 1997 Dec 06; 109(20):775-81. PubMed ID: 9493155
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
    Hohaus S, Wallwiener D, Martin S, Voso MT, Huober J, Fersis N, Bastert G, Haas R.
    Semin Oncol; 1998 Apr 06; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
    [Abstract] [Full Text] [Related]

  • 29. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast.
    Schwartzberg L, Weaver C, Lewkow L, McAneny B, Zhen B, Birch R, West W, Tauer K, Buckner C.
    Bone Marrow Transplant; 1999 Nov 06; 24(9):981-7. PubMed ID: 10556957
    [Abstract] [Full Text] [Related]

  • 30. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Fetscher S, Hasse J, Frommhold H, Pressler K, Mertelsmann R, Engelhardt R, Kanz L.
    Semin Oncol; 1998 Feb 06; 25(1 Suppl 2):42-8. PubMed ID: 9535211
    [Abstract] [Full Text] [Related]

  • 31. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
    Bone Marrow Transplant; 1997 May 06; 19(10):983-8. PubMed ID: 9169642
    [Abstract] [Full Text] [Related]

  • 32. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U.
    J Clin Oncol; 2006 Aug 20; 24(24):3919-26. PubMed ID: 16921043
    [Abstract] [Full Text] [Related]

  • 33. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
    Ahmed T, Kancherla R, Qureshi Z, Mittelman A, Seiter K, Mannancheril A, Puccio C, Chun HG, Bar M, Lipshutz M, Ali MF, Goldberg R, Preti R, Lake D, Durrani H, Farley T.
    Bone Marrow Transplant; 2000 May 20; 25(10):1041-5. PubMed ID: 10828863
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer.
    Vaughan WP, Reed EC, Edwards B, Kessinger A.
    Bone Marrow Transplant; 1994 May 20; 13(5):619-24. PubMed ID: 7914447
    [Abstract] [Full Text] [Related]

  • 36. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN.
    Cancer; 2006 Jun 01; 106(11):2327-36. PubMed ID: 16639731
    [Abstract] [Full Text] [Related]

  • 37. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD.
    J Clin Oncol; 2005 Apr 01; 23(10):2191-200. PubMed ID: 15767638
    [Abstract] [Full Text] [Related]

  • 38. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 39. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 40. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J.
    Clin Cancer Res; 1996 Sep 01; 2(9):1509-13. PubMed ID: 9816327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.